The effect of L-deprenyl, D-deprenyl and MDL72974 on mitochondrial respiration: A possible mechanism leading to an adaptive increase in superoxide dismutase activity

Molecular Brain Research

Volumn 49, Issue 1-2, 1997, Pages 127-136

  Thiffault, C ^a,c   Quirion, R ^a,c   Poirier, J ^b,c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Dopamine; Enzyme regulation; L Deprenyl; Mechanism; Monoamine oxidase inhibitor; Norepinephrine; Respiratory chain; Superoxide dismutase

Indexed keywords

ADENOSINE TRIPHOSPHATE; COPPER ZINC SUPEROXIDE DISMUTASE; MANGANESE SUPEROXIDE DISMUTASE; MOFEGILINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SELEGILINE; SUCCINATE DEHYDROGENASE (UBIQUINONE); SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOSYNTHESIS; CONTROLLED STUDY; CORPUS STRIATUM; ENZYME ACTIVITY; ENZYME REGULATION; MALE; MITOCHONDRIAL RESPIRATION; NONHUMAN; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PRIORITY JOURNAL; RAT;

ALLYL COMPOUNDS; ANIMALS; ANTIPARKINSON AGENTS; BRAIN; BUTYLAMINES; CATTLE; CEREBELLUM; CORPUS STRIATUM; DOPAMINE; ERYTHROCYTES; KINETICS; MICE; MICE, INBRED C57BL; MICE, INBRED STRAINS; MITOCHONDRIA; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; NOREPINEPHRINE; OXIDATIVE STRESS; OXYGEN CONSUMPTION; RATS; SELEGILINE; STEREOISOMERISM; SUPEROXIDE DISMUTASE;

ANIMALIA;

EID: 0030657020     PISSN: 0169328X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-328X(97)00135-6     Document Type: Article

References (67)

1. + induced oxygen radical formation with mitochondrial enzymes. Free Rad. Biol. Med. 15:1993;181-186.
2. Anton A.M., Sayre D.F. A study of the factors affecting the aluminum oxide-trihydroxyindole procedure for the analysis of catecholamines. J. Pharmacol. Exp. Ther. 138:1962;360-375.
3. Berry M.D., Juorio A.V., Paterson I.A. Possible mechanisms of action of (-)-deprenyl and other MAO-B inhibitors in some neurologic and psychiatric disorders. Prog. Neurobiol. 44:1994;141-161.
4. Bondiolotti G.P., Galva M.D., Villa F., Sciaba L., Picotti G.B. In vitro effects on monoamine uptake and release by the reversible monoamine oxidase-B inhibitors lazabemide and n-(2-aminoethyl)-p-chlorobenzamide: a comparison with L-deprenyl. Biochem. Pharmacol. 50:1995;97-102.
5. Boulton A.A., Juorio A.V., Paterson I.A. Phenylethylamine in the CNS: effects of monoamine oxidase inhibiting drugs, deuterium substitution and lesions and its role in the neuromodulation of catecholaminergic neurotransmission. J. Neural Transm. Suppl. 29:1990;119-129.
6. Boveris A., Chance B. The mitochondrial generation of hydrogen peroxide. General properties and effect of hyperbaric oxygen. Biochem. J. 134:1973;707-716.
7. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
8. Brown-Peterson N.J., Begonia G.B., Salin M.L. Alterations in oxidative activity and superoxide dismutase in halobacterium halobium in response to aerobic respiratory inhibitors. Free Rad. Biol. Med. 18:1995;249-256.
9. Carrillo M.-C., Kanai S., Nokubo M., Kitani K. (-)-Deprenyl induces activities of both superoxide dismutase and catalase but not of glutathione peroxidase in the striatum of young male rats. Life Sci. 48:1991;517-521.
10. Carrillo M.-C., Kitani K., Kanai S., Sato Y., Ivy G.O. The ability of (-)-deprenyl to increase superoxide dismutase activities in the rat is tissue and brain region selective. Life Sci. 50:1992;1985-1992.
11. Carrillo M.-C., Kanai S., Sato Y., Nokubo M., Ivy G.O., Kitani K. The optimal dosage of (-)-deprenyl for increasing superoxide dismutase activities in several brain regions decreases with age in male Fischer 344 rats. Life Sci. 52:1993;1925-1934.
12. Chiba K., Trevor A., Castagnoli N. Jr. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem. Biophys. Res. Commun. 120:1984;574-578.
13. Chiueh C.C., Huang S.J., Murphy D.L. Enhanced hydroxyl radical generation by 2′-methyl analog of MPTP: suppression by clorgyline and deprenyl. Synapse. 11:1992;346-348.
14. Clark J.B., Nicklas W.J. The metabolism of rat brain mitochondria. J. Biol. Chem. 245:1970;4724-4731.
15. Clow A., Hussain T., Glover V., Sandler M., Dexter D.T., Walker M. (-)-Deprenyl can induce soluble superoxide dismutase in rat striata. J. Neural Transm. - Gen. Sect. 86:1991;77-80.
16. Clow A., Hussain T., Glover V., Sandler M., Walker M., Dexter D.T. Pergolide can induce soluble superoxide dismutase in rat striata. J. Neural Transm. - Gen. Sect. 90:1992;27-31.
17. Clow A., Freestone C., Lewis E., Dexter D.T., Sandler M., Glover V. The effect of pergolide and MDL 72974 on rat brain CuZn superoxide dismutase. Neurosci. Lett. 164:1993;41-43.
18. Cohen G., Spina M.B. Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. Ann. Neurol. 26:1989;689-690.
19. Coyle J.T., Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science. 262:1993;689-695.
20. Da Prada M., Kettler R., Keller H.H., Burkard W.P., Muggli-Maniglio D., Haefely W.E. Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J. Pharmacol. Exp. Ther. 248:1989;400-414.
21. Dow J., Piriou F., Wolf E., Dulery B.D., Haegele K.D. Novel carbamate metabolites of mofegiline, a primary amine monoamine oxidase B inhibitor, in dogs and humans. Drug Metab. Dispos. 22:1994;738-749.
22. Elizan T.S., Yahr M.D., Moros D.A., Mendoza M.R., Pang S., Bodian C.A. Selegiline as an adjunct to conventional levodopa therapy in Parkinson's disease. Experience with this type B monoamine oxidase inhibitor in 200 patients. Arch. Neurol. 46:1989;1280-1283.
23. Ernster L., Dallner G. Biochemical, physiological and medical aspects of ubiquinone function. Biochim. Biophys. Acta - Mol. Basis Dis. 1271:1995;195-204.
24. Fang J., Yu P.H. Effect of L-deprenyl, its structural analogues and some monoamine oxidase inhibitors on dopamine uptake. Neuropharmacology. 33:1994;763-768.
25. Felner A.E., Waldmeier P.C. Cumulative effects of irreversible MAO inhibitors in vivo. Biochem. Pharmacol. 28:1979;995-1002.
26. Frank L. Prolonged survival after paraquat. Role of the lung antioxidant enzyme systems. Biochem. Pharmacol. 30:1981;2319-2324.
27. Fridovich I. The biology of oxygen radicals. Science. 209:1978;875-877.
28. Goridis C., Neff N.H. Monoamine oxidase: an approximation of turnover rates. J. Neurochem. 18:1971;1673-1682.
29. Götz M.E., Dirr A., Burger R., Rausch W.D., Riederer P. High dose selegiline augments striatal ubiquinol in mouse: an indication of decreased oxidative stress or of interference with mitochondrial respiration? a pilot study. J. Neural Transm. Suppl. 46:1995;149-156.
30. Graham D.G. Catecholamine toxicity: a proposal for the molecular pathogenesis of manganese neurotoxicity and Parkinson's disease. NeuroToxicology. 5:1984;83-95.
31. Heikkila R.E., Nicklas W.J., Vyas I., Duvoisin R.C. Dopaminergic toxicity of rotenone and the 1-methyl-4-phenylpyridinium ion after their stereotaxic administration to rats: implication for the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity. Neurosci. Lett. 62:1985;389-394.
32. Heikkila R.E., Terleckyj I., Sieber B.A. Monoamine oxidase and the bioactivation of MPTP and related neurotoxins: relevance to DATATOP. J. Neural Transm. Suppl. 32:1990;217-227.
33. Heinonen E.H., Anttila M.I., Lammintausta R.A.S. Pharmacokinetic aspects of L-deprenyl (selegiline) and its metabolites. Clin. Pharmacol. Ther. 56:1994;742-749.
34. Karoum F., Chuang L.W., Eisler T., Calne D.B., Liebowitz M.R., Quitkin F.M., Klein D.F., Wyatt R.J. Metabolism of (-)deprenyl to amphetamine and methamphetamine may be responsible to deprenyl's therapeutic benefit: a biochemical assessment. Neurology. 32:1982;503-509.
35. Knoll J. The possible mechanisms of action of (-)-deprenyl in Parkinson's disease. J. Neural Transm. 43:1978;177-198.
36. Knoll J. R-(-)-deprenyl (Selegiline, Movergan) facilitates the activity of the nigrostriatal dopaminergic neuron. J. Neural Transm. Suppl. 25:1987;45-66.
37. Knoll J. The striatal dopamine dependency of life span in male rats. Longevity study with (-)-deprenyl. Mech. Ageing Dev. 46:1988;237-262.
38. Knoll J., Miklya I. Multiple, small dose administration of (-)-deprenyl enhances catecholaminergic activity and diminishes serotoninergic activity in the brain and these effects are unrelated to MAO-B inhibition. Arch. Int. Pharmacodyn. Ther. 328:1994;1-15.
39. Lai J.C.K., Leung T.K.C., Guest J.F., Lim L., Davison A.M. The monoamine oxidase inhibitors clorgyline and L-deprenyl also affect the uptake of dopamine, noradrenaline and serotonin by rat brain synaptosomal preparations. Biochem. Pharmacol. 29:1980;2763-2767.
40. Lees A.J. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Br. Med. J. 311:1995;1602-1607.
41. Mahmood I., Peters D.K., Mason W.D. The pharmacokinetics and absolute bioavailability of selegiline in the dog. Biopharm. Drug Disp. 15:1994;653-664.
42. Magyar K., Vizi E.S., Ecseri Z., Knoll J. Comparative pharmacological analysis of the optical isomers of phenyl-isopropyl-methyl-propinylamine (E-250). Acta Physiol. Acad. Sci. Hung. 32:1967;377-387.
43. Marey-Semper I., Gelman M., Lévi-Strauss M. The high sensitivity to rotenone of striatal dopamine uptake suggests the existence of a constitutive metabolic deficiency in dopaminergic neurons from the substantia nigra. Eur. J. Neurosci. 5:1993;1029-1034.
44. McCord J.M., Fridovich I. Superoxide dismutase: an enzymatic function for erythrocuprein (hemocuprein). J. Biol. Chem. 244:1969;6049-6055.
45. Misra H.P., Fridovich I. The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J. Biol. Chem. 247:1972;3170-3175.
46. Müller T.H., Unsicker K. High performance liquid chromatography with electrochemical detection as a highly efficient tool for studying catecholamine systems. I. Quantification of noradrenaline, adrenaline and dopamine in cultured adrenal medullary cells J. Neurosci. Methods. 4:1981;39-52.
47. Nicklas W.J., Vyas I., Heikkila R.E. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-penyl-1,2,3,6-tetrahydropyridine. Life Sci. 36:1985;2503-2508.
48. Nyman M., Whittaker V.P. The distribution of adenosine triphosphate in subcellular fractions of brain tissue. Biochem. J. 87:1963;248-255.
49. Ogawa N., Asanuma M., Kondo Y., Hirata H., Nishibayashi S., Mori A. Changes in lipid peroxidation, Cu/Zn-superoxide dismutase and its mRNA following an intracerebroventricular injection of 6-hydroxydopamine in mice. Brain Res. 646:1994;337-340.
50. Oreland L., Arai Y., Stenström A. The effect of deprenyl (selegiline) on intra- and extraneuronal dopamine oxidation. Acta Neurol. Scand. Suppl. 95:1983;81-85.
51. Paterson I.A., Davis B.A., Durden D.A., Juorio A.V., Yu P.H., Ivy G., Milgram W., Mendonca A., Wu P., Boulton A.A. Inhibition of MAO-B by (-)-deprenyl alters dopamine metabolism in the macaque (Macaca fascicularis) brain. Neurochem. Res. 20:1995;1503-1510.
52. Paterson I.A., Juorio A.V., Boulton A.A. 2-Phenylethylamine: a modulator of catecholamine transmission in the mammalian central nervous system? J. Neurochem. 55:1990;1827-1837.
53. Renner K.J., Luine V.N. Determination of monoamines in brain nuclei by high performance liquid chromatography with electrochemical detection: young vs. middle aged rats. Life Sci. 34:1984;2193-2199.
54. Reynolds G.P., Riederer P., Sandler M., Jellinger K., Seemann D. Amphetamine and 2-phenylethylamine in post-mortem Parkinson's brain after (-)-deprenyl administration. J. Neural Transm. 43:1978;271-277.
55. Rossetti Z.L., Sotgiu A., Sharp D.E., Hadjiconstantinou M., Neff N.H. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and free radicals in vitro. Biochem. Pharmacol. 37:1988;4573-4574.
56. Sjostrom K., Crapo J.D. Adaptation to oxygen by preexposure to hypoxia: enhanced activity of manganese superoxide dismutase. Bull. Eur. Physiolpathol. Resp. 17(Suppl.):1981;111-116.
57. Sohal R.S., Brunk U.T. Mitochondrial production of pro-oxidants and cellular senescence. Mut. Res. 275:1992;295-304.
58. Stevens J.B., Autor A.P. Induction of superoxide dismutase by oxygen in neonatal rat lung. J. Biol. Chem. 252:1977;3509-3514.
59. The Parkinson Study Group Effect of deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 321:1989;1364-1371.
60. The Parkinson Study Group Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 28:1993;176-183.
61. Thiffault C., Aumont N., Quirion R., Poirier J. Effect of MPTP and L-deprenyl on antioxidant enzymes and lipid peroxidation levels in mouse brain. J. Neurochem. 65:1995;2725-2733.
62. Turrens J.F., Boveris A. Generation of superoxide anion by the NADH dehydrogenase of bovine heart mitochondria. Biochem. J. 191:1980;421-427.
63. Van de Water B., Zoeteweij J.P., De Bont H.J.G.M., Nagelkerke J.F. Inhibition of succinate: ubiquinone reductase and decrease of ubiquinol in nephrotic cyteine S-conjugate-induced oxidative cell injury. Mol. Pharmacol. 48:1995;928-937.
64. Weisiger R.A., Fridovich I. Superoxide dismutase: organelle specificity. J. Biol. Chem. 248:1973;3582-3592.
65. Wurtman R.J., Axelrod J. A sensitive and specific assay for the estimation of monoamine oxidase. Biochem. Pharmacol. 12:1963;1439-1441.
66. Zreika M., Fozard J.R., Dudley M.W., Bey P., McDonald I.A., Palfreyman M.G. MDL 72,974: a potent and selective enzyme-activated irreversible inhibitor of monoamine oxidase type B with potential for use in Parkinson's disease. J. Neural Transm. - Park. Dis. Dement. Sect. 1:1989;243-254.
67. Zsilla G., Földi P., Held G., Székely A.M., Knoll J. The effect of repeated doses of (-)-deprenyl on the dynamics of monoaminergic transmission. Comparison with clorgyline. Pol. J. Pharmacol. Pharm. 38:1986;57-67.